✦ LIBER ✦

The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents

✍ Scribed by Elias Jabbour; Jorge Cortes; Francis Giles; Susan O’Brien; Hagop Kantarjian

Book ID: 107384267
Publisher: Springer-Verlag
Year: 2006
Tongue: English
Weight: 275 KB
Volume: 1
Category: Article
ISSN: 1776-2596
DOI: 10.1007/s11523-006-0032-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term prognostic impact of the use o

Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib

✍ Fabio P. S. Santos; Yesid Alvarado; Hagop Kantarjian; Dushyant Verma; Susan O'Br 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 1 views

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH

Choosing the best treatment strategy for

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history

✍ Jabbour, E; Hochhaus, A; Cortes, J; La Rosée, P; Kantarjian, H M 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 326 KB

Pilot study of lonafarnib, a farnesyl tr

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

✍ Gautam Borthakur; Hagop Kantarjian; George Daley; Moshe Talpaz; Susan O'Brien; G 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

Imatinib as the first-line treatment of

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

✍ Daniela Zackova; Hana Klamova; Ladislav Dusek; Jan Muzik; Katerina Machova Polak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 3 views

A novel insertion mutation of K294RGG wi

A novel insertion mutation of K294RGG withinBCR-ABLkinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis

✍ Katsuya Sakai; Yuichi Ishikawa; Yumiko Mori; Miki Kobayashi; Chisako Iriyama; Yu 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 331 KB